Hurwitz E S, Barrett M J, Bregman D, Gunn W J, Schonberger L B, Fairweather W R, Drage J S, LaMontagne J R, Kaslow R A, Burlington D B
N Engl J Med. 1985 Oct 3;313(14):849-57. doi: 10.1056/NEJM198510033131403.
Between February and May 1984, we conducted a pilot study to examine the methods for a larger study of a previously reported relation between Reye's syndrome and medications. Thirty patients with Reye's syndrome, whose diagnosis was confirmed by an expert panel, and 145 controls were matched for age, race (black or not black), and antecedent illness (respiratory infection, chickenpox, or diarrhea) and selected from the same hospital, emergency room, or school, or identified by random digit dialing. Significantly more cases (93 per cent, 28 of 30) than members of each of the four control groups or all controls combined (46 per cent, 66 of 145) had received salicylates during matched antecedent illnesses (odds ratio of all 30 cases vs. all controls = 16.1; lower 95 per cent confidence limit = 4.6). The prevalence and mean severity score of signs, symptoms, and selected events during the antecedent illness tended to be lower among cases than controls. Thus, differences in the severity of this illness between cases and controls did not explain differences in medication exposures. This pilot study suggests an association between Reye's syndrome and the use of salicylates during an antecedent illness.
1984年2月至5月期间,我们进行了一项试点研究,以检验对先前报道的瑞氏综合征与药物之间关系进行更大规模研究的方法。30例瑞氏综合征患者,其诊断由一个专家小组确认,以及145名对照者按年龄、种族(黑人或非黑人)和前驱疾病(呼吸道感染、水痘或腹泻)进行匹配,并从同一医院、急诊室或学校选取,或通过随机数字拨号识别。在匹配的前驱疾病期间,显著更多的病例(93%,30例中的28例)比四个对照组中的任何一组或所有对照组的总和(46%,145例中的66例)接受了水杨酸盐治疗(所有30例病例与所有对照的比值比=16.1;95%置信下限=4.6)。前驱疾病期间体征、症状和选定事件的患病率和平均严重程度评分在病例组中往往低于对照组。因此,病例组和对照组之间该疾病严重程度的差异并不能解释药物暴露的差异。这项试点研究表明瑞氏综合征与前驱疾病期间使用水杨酸盐之间存在关联。